Introduction
============

Esophageal cancer is one of the most common malignant tumors of the digestive system that has a poor prognosis.[@b1-ott-9-6751] Surgery remains to be the primary treatment for esophageal cancer; however, the open esophagectomy (OE) is a relatively high invasive surgery, which may lead to several morbidities and prominent mortality as well.[@b2-ott-9-6751] As a supplement to the traditional open surgery, minimally invasive esophagectomy (MIE) was first introduced to treat esophageal cancer \~20 years ago.[@b3-ott-9-6751] With the developing skills and increasing experiences in laparoscopy and thoracoscopy in thoracic and stomach surgery, MIE has become a frequent choice for esophageal cancer nowadays. Minimally invasive surgery is assumed to reduce surgical injury on the one hand and improve patients' prognosis on the other. Guo et al[@b4-ott-9-6751] had conducted a prospective randomized study and their results indicated that MIE had some short-term benefits such as less hemorrhage, better recovery, and fewer complications but no difference in long-term survival rate in comparison with open surgery. A recently randomized trial conducted by Maas et al[@b5-ott-9-6751] suggests that MIE is associated with a better one-year quality of life compared with OE. Both studies were performed based on a small sample size, so that more evidences are needed to prove that MIE is an applicable alternative from which patients can gain more benefits compared with the open surgery. Several relevant meta-analyses had been performed to evaluate the safety and effectiveness of the two surgeries, while most of them were based on retrospective studies. Therefore, this meta-analysis was conducted through only randomized controlled trials and prospective studies in order to clarify whether MIE could improve the short-term outcomes and overall survival of patients with esophageal cancer.

Methods
=======

Data sources and literature search strategy
-------------------------------------------

Literature review was conducted by two investigators (LL and YCR) through online data sources MEDLINE, EMBASE, and [ClinicalTrials.gov](http://ClinicalTrials.gov) (up to Jan 2016), using the search terms "esophageal cancer", "VATS", "MIE", "thoracoscopic esophagectomy", "laparoscopic esophagectomy", and "Open esophagectomy".

Study selection
---------------

Inclusion criteria were: 1) randomized controlled trials or prospective studies; 2) patients who underwent esophagectomy for esophageal cancer; 3) comparing MIE with OE on interest outcomes such as surgical results, postoperative complications, and survival rate; 4) research of human beings; and 5) written in English language.

Study quality assessment
------------------------

The quality of the studies was assessed by The Newcastle-Ottawa quality assessment Scale (NOS), and the total score of each study should not be \<6, which is considered as high quality and eligible for the research.

Data extraction
---------------

The data on characteristics of studies, surgical outcomes, postoperative complications, and overall survival were extracted from the selected studies by one author (LL) and checked by another author (XXW). Information included are study name, publication year, study design, number of patients, interventions, age, sex, tumor stage, tumor location, pathology, operative time, operation blood loss, numbers of lymph node harvest, R0 resection, reoperation, in-hospital mortality, respiratory complications, cardiovascular complications, anastomotic leakage, anastomotic stricture, chylothorax recurrent laryngeal paralysis, and overall survival.

Statistical analysis
--------------------

Review Manager Version 5.3 was used to perform meta-analysis, and the estimated survival data were obtained from the Kaplan--Meier curves using GetData Graph Digitizer software. The data can be synthesized only when the number of studies exceeds two. Measurement data reported as mean ± SD were adopted, and odds ratio (OR) or risk ratio (RR) was calculated. Pooled weighted mean difference (WMD) was used in enumeration data and hazard ratio in survival data. All the statistical results use random-effect models. Heterogeneity was assessed by *χ*^2^ and *I*^2^ and publication bias by funnel plots. The subgroup analysis was performed based on the study design.

Results
=======

Eligible studies and characteristics of studies
-----------------------------------------------

In this meta-analysis, 20 studies were included, four randomized controlled trials and 16 prospective studies ([Figure 1](#f1-ott-9-6751){ref-type="fig"}). A total of 6,025 patients were joined into research, of whom 2,091(35%) underwent MIE and 3,934 (65%) underwent OE. The characteristics of the studies are shown in [Table 1](#t1-ott-9-6751){ref-type="table"}.

Meta-analysis of postoperative outcomes
---------------------------------------

### Surgical outcomes

MIE group has lower operative blood loss (WMD = −283.61, 95% CI =−451.69 to −115.52, *P*=0.0009; [Figure 2A](#f2-ott-9-6751){ref-type="fig"}) and longer operation time (WMD =44.42, 95% CI =10.95--77.88, *P*=0.009; [Figure 2B](#f2-ott-9-6751){ref-type="fig"}) than the OE group. There are no statistical significances of lymph node harvest (WMD =−0.80, 95% CI =−4.63--3.03, *P*=0.68; [Figure 2C](#f2-ott-9-6751){ref-type="fig"}), R0 resection (RR =1.03, 95% CI =0.98--1.08, *P*=0.21; [Figure 2D](#f2-ott-9-6751){ref-type="fig"}) between the two groups.

### Postoperative complications

Patients in the MIE group get less respiratory complications than in the OE group (RR =0.74, 95% CI =0.58--0.94, *P*=0.01) and in the randomized-controlled trial (RCT) studies subgroup (RR =0.34, 95% CI =0.21--0.53, *P*=0.01, *P*\<0.00001), while in the prospective studies subgroup (RR =0.83, 95% CI =0.67--1.04, *P*=0.11; [Figure 3](#f3-ott-9-6751){ref-type="fig"}). There are no statistical significances of anastomotic leakage (OR=0.84, 95% CI =0.59--1.18, *P*=0.32; [Figure 4](#f4-ott-9-6751){ref-type="fig"}), anastomotic stricture (OR =1.76, 95% CI =0.78--3.97, *P*=0.18; [Figure 5A](#f5-ott-9-6751){ref-type="fig"}), in-hospital mortality (OR =0.84, 95% CI =0.60--1.19, *P*=0.33; [Figure 5B](#f5-ott-9-6751){ref-type="fig"}), reoperation (OR =1.10, 95% CI =0.59--2.04, *P*=0.77; [Figure 5C](#f5-ott-9-6751){ref-type="fig"}), cardiovascular complications (OR =0.90, 95% CI =0.64--1.28, *P*=0.57; [Figure 6A](#f6-ott-9-6751){ref-type="fig"}), chylothorax (OR =0.90, 95% CI =0.47--1.74, *P*=0.76; [Figure 6B](#f6-ott-9-6751){ref-type="fig"}), and recurrent laryngeal paralysis (OR =1.31, 95% CI =0.67--2.55, *P*=0.43; [Figure 6C](#f6-ott-9-6751){ref-type="fig"}) between the two groups.

### Survival outcome

The MIE group has a better overall survival than the open group (hazard ratio =0.54, 95% CI =0.42--0.70, *P*\<0.00001; [Figure 7](#f7-ott-9-6751){ref-type="fig"}).

All outcomes of interest are listed in [Table 2](#t2-ott-9-6751){ref-type="table"}, and the funnel plots display the publication bias of respiratory complications ([Figure 8A](#f8-ott-9-6751){ref-type="fig"}), cardiovascular complications ([Figure 8B](#f8-ott-9-6751){ref-type="fig"}), in-hospital mortality ([Figure 8C](#f8-ott-9-6751){ref-type="fig"}), and anastomotic leakage ([Figure 8D](#f8-ott-9-6751){ref-type="fig"}).

Discussion
==========

The MIE was first introduced in 1980s, and the study of Cuschieri et al[@b3-ott-9-6751] indicated that MIE was as effective as open surgery. In the last 20 years, with the sophisticated technique of thoracoscope and laparoscope, minimally invasive surgery shows significant superiority in reducing surgical injury and increasing survival rate in thoracic and abdominal operations.[@b6-ott-9-6751],[@b7-ott-9-6751] Now, MIE has been used more and more frequently in esophageal cancer, as it has been considered as a good method to reduce the high morbidity and mortality compared with the traditional OE. There are two major operation methods of MIE, including combined thoracoscopic--laparoscopic esophagectomy, which is also known as total MIE and thoracoscopic-assisted esophagectomy or laparoscopic-assisted esophagectomy -- the so-called hybrid MIE. This study compared the open surgery with both hybrid MIE and total MIE. Due to the complexity of the esophagectomy, different surgery modalities might lead to various surgical complications, but the main morbidities are pulmonary complications, cardiac complications, anastomotic complications, and so forth. Therefore, the focus was on comparing the postoperative outcomes as mentioned earlier.

The studies about the comparison of the two surgeries are primarily retrospective studies as most of the clinical trials that are registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) are still unfinished. So far, only four randomized studies have done their jobs and that is the reason why the majority of the existed meta-analyses were based on retrospective studies. Among those meta-analyses that had been done before us: Sgourakis et al[@b8-ott-9-6751] compared postoperative outcomes and survival between MIE and OE and revealed that both groups have the same in-hospital results and prognosis; Nagpal et al[@b9-ott-9-6751] analyzed postoperative outcomes, including the 30-day mortality and anastomotic leakage of MIE and OE and revealed that there was no significant difference in the mortality; Zhou et al[@b10-ott-9-6751],[@b11-ott-9-6751] compared anastomotic leakage and in-hospital mortality between the two groups, and the outcome showed that MIE has superiority over OE as the former could reduce the in-hospital mortality rate; however, there was no evidence that MIE could decrease the anastomotic leakage; and Guo et al[@b12-ott-9-6751] indicated that MIE can achieve significant long-term survival rates and reduce perioperative complications.

In this study, only randomized trials and prospective studies were included, totally 20 studies were pooled to compare the outcomes between MIE and OE. Though Xiong et al[@b13-ott-9-6751] had done a similar work before us, they included only three RCTs and two prospective studies. Therefore, our evidence is more sufficient and reliable. The results showed that MIE had advantage in reducing the operative blood loss, but the outcome has great heterogeneity (*I*^2^=87%) that may be attributable to the following reasons: first, there are various approaches in both MIE and OE, and the surgery styles vary from one operation team to another as well. Second, most of the studies use the median ± interquartile range, instead of mean ± SD, which is unavailable to run meta-analysis, that in turn influences the result of synthesis. Patients undergoing MIE get less respiratory complications than OE. In order to figure out the source of its heterogeneity (*I*^2^=67%) we did a subgroup analysis. The heterogeneity is much more significant in the subgroup of prospective studies (*I*^2^=57%) than that in the prospective studies (*I*^2^=0%), and it suggests that the study design is the main cause of heterogeneity. Respiratory morbidities, especially pulmonary complications, which are the most important factors, could impact the prognosis of the patients. A lot of patients get dysfunctions of respiratory system after esophagectomy.[@b14-ott-9-6751]--[@b17-ott-9-6751] The reasons that MIE can reduce respiratory complications might be as follows: first, the exquisite operation procedure could decrease the surgical trauma and do less harm to the chest wall or pulmonary tissues. Next, less surgical injury can free the patients from the pain followed by and postoperative pain makes patients less willing to cough, which aggravates the pulmonary infection. The results demonstrated that there are no statistical differences with respect to number of lymph nodes harvest, R0 resection, reoperation, in-hospital mortality, cardiovascular complications, anastomotic leakage, anastomotic stricture, chylothorax, and recurrent laryngeal paralysis between the two groups, but the MIE group has a better overall survival than the open group. The reason could be explained by the amplification effect of the thoracoscope or laparoscope, through which the tumor tissues and relevant lymph nodes could be dissected more accurately; therefore, the MIE can get a better prognosis.

This study has also some limitations. In the first place, except for operation blood loss and operative time, there were significant heterogeneities in number of lymph nodes harvest, reoperation, and anastomotic stricture. The reasons resemble those explained in operation blood loss. In the second place, several included studies did not report the outcomes completely, yet access to the original data was unavailable. Finally, lack of large, multiple center, randomized-controlled trials might reduce the effectiveness of the research. Therefore, the work needs to be improved when there are more RCTs.

Conclusion
==========

Patients who have undergone the MIE have lower blood loss and less respiratory complications in comparison with the OE. They can also gain the same benefits of postoperative outcomes composing lymph node harvest and margin of resection as the open group. The estimated overall survival rate is improved in the MIE group. That being said, MIE is a better choice for esophageal cancer patients.
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![Funnel plots of postoperative complications.\
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###### 

Characteristics and demographics of included studies

  Study                                 Year   Country/district             Design        NOS score   Intervention                                Cases   Age, years median (IQ range) and mean ± SD   Sex (m/f)   TNM stage (0/I/II/III/IV)   Pathology (adeno/spuam/other)
  ------------------------------------- ------ ---------------------------- ------------- ----------- ------------------------------------------- ------- -------------------------------------------- ----------- --------------------------- -------------------------------
  Bailey et al[@b18-ott-9-6751]         2013   UK                           Prospective   7           Laparoscopically assisted esophagectomy     39      65 (37--78)                                  32/7        NA                          31/6/2
                                                                                                      Open esophagectomy                          31      62 (38--78)                                  27/4                                    27/3/1
  Biere et al[@b19-ott-9-6751]          2012   the Netherlands              RCT           8           Minimally invasive esophagectomy            59      62 (34--75)                                  43/16       1/4/26/11/4/9               24/35/0
                                                                                                      Open esophagectomy                          56      62 (42--75)                                  46/10       0/4/22/14/5/7               36/19/1
  Bonavina et al[@b20-ott-9-6751]       2015   Italy                        Prospective   6           Thoracoscopic-prone esophagectomy           80      61.5 (53--70)                                46/34       0/25/25/23/7                9/68/3
                                                                                                      Hybrid Ivor Lewis                           80      63.5 (55.4--68.5)                            71/9        0/15/22/31/12               63/15/2
  Guo et al[@b4-ott-9-6751]             2013   People's Republic of China   RCT           8           Thoracoscopy combined laparoscopy           111     57.3±11.8                                    68/43       0/24/7/80/0                 NA
                                                                                                      Open transthoracic esophagectomy            110     60.8±12.4                                    72/38       0/31/5/74/0                 
  Hamouda et al[@b21-ott-9-6751]        2010   UK                           Prospective   7           Laparoscopic of Ivor-Lewis esophagectomy    26      62                                           25/1        NA                          21/4/1
                                                                                                      Open Ivor Lewis esophagectomy               24      60                                           23/1                                    21/3/0
  Kinjo et al[@b22-ott-9-6751]          2012   Japan                        Prospective   7           Thoracoscopic--laparoscopic esophagectomy   72      62.7±7.4                                     58/14       0/21/26/16/9                0/71/1
                                                                                                      Thoracoscopic esophagectomy                 34      64.2±8.8                                     29/5        0/11/7/9/7                  3/31/0
                                                                                                      Open esophagectomy                          79      63.3±8.6                                     70/9        0/18/27/20/14               3/71/5
  Kothari et al[@b23-ott-9-6751]        2011   India                        Prospective   7           Minimally invasive surgery                  34      NA                                           NA          NA                          NA
                                                                                                      Ivor Lewis esophagectomy                    28                                                                                           
  Law et al[@b24-ott-9-6751]            1997   Hong Kong                    Prospective   6           Thoracoscopy                                18      66 (43--80)                                  13/5        1/1/3/13/0                  NA
                                                                                                      Thoracotomy                                 63      63 (36--84)                                  55/8        0/4/11/45/3                 
  Lee et al[@b25-ott-9-6751]            2011   Taiwan                       Prospective   7           Total minimally invasive esophagectomy      30      59.73±10.32                                  30/0        2/3/11/12/2                 1/29/0
                                                                                                      Hybrid minimally invasive esophagectomy     44      59.70±11.17                                  43/1        12/13/14/5/1                1/43/0
                                                                                                      Open esophagectomy                          64      56.58±11.60                                  61/3        7/17/25/14/1                5/59/0
  Maas et al[@b26-ott-9-6751]           2014   the Netherlands              RCT           8           Minimally invasive esophagectomy            14      65 (56--75)                                  10/4        NA                          13/1/0
                                                                                                      Open esophagectomy                          13      62 (52--74)                                  12/1                                    11/2/0
  Maas et al[@b5-ott-9-6751]            2015   the Netherlands              RCT           8           Minimally invasive esophagectomy            59      62 (34--75)                                  43/16       1/4/26/11/4                 35/24/0
                                                                                                      Open esophagectomy                          56      62 (42--75)                                  46/10       0/4/22/14/5                 36/19/1
  Noble et al[@b27-ott-9-6751]          2013   UK                           Prospective   7           Minimally invasive esophagectomy            53      66 (45--85)                                  43/10       NA                          47/4/1
                                                                                                      Ivor Lewis esophagectomy                    53      64 (36--81)                                  45/8                                    48/3/0
  Parameswaran et al[@b28-ott-9-6751]   2013   UK                           Prospective   7           Total minimally invasive esophagectomy      36      64 (45--84)                                  24/12       6/6/13/10/0                 22/8/5
                                                                                                      Laparoscopic-assisted esophagectomy         31      67 (48--79)                                  23/8        1/5/12/13/0                 27/3/0
                                                                                                      Open esophagectomy                          19      64 (51--77)                                  15/4        0/0/8/11/0                  16/3/0
  Perry et al[@b29-ott-9-6751]          2009   USA                          Prospective   6           Laparoscopic inversion esophagectomy        21      69±8                                         18/3        NA                          NA
                                                                                                      Open transhiatal esophagectomy              21      61±9                                         17/4                                    
  Pham et al[@b30-ott-9-6751]           2010   USA                          Prospective   7           Thoracoscopic--laparoscopic esophagectomy   44      63±8.6                                       41/3        0/6/14/18/2                 34/8/0
                                                                                                      Ivor Lewis esophagectomy                    46      61±10.7                                      33/13       0/7/13/18/1                 34/6/2
  Safranek et al[@b31-ott-9-6751]       2010   UK                           Prospective   6           Total minimally invasive esophagectomy      41      64 (41--74)                                  25/16       2/7/17/15/0                 23/17/1
                                                                                                      Hybrid minimally invasive esophagectomy     34      63 (44--76)                                  28/6        2/2/14/16/0                 29/3/2
                                                                                                      Open esophagectomy                          46      60 (44--77)                                  38/8        0/6/11/29/0                 43/3/0
  Scarpa et al[@b32-ott-9-6751]         2015   Italy                        Prospective   7           Hybrid minimally invasive esophagectomy     34      62 (52--70)                                  25/9        11/5/13/5/0                 24/10/0
                                                                                                      Open esophagectomy                          34      64 (56--70)                                  27/7        5/6/18/4/1                  24/10/0
  Schoppmann et al[@b33-ott-9-6751]     2010   Austria                      Prospective   7           Minimally invasive esophagectomy            31      61.5 (35.7--74.8)                            6/25        0/9/9/11/0                  17/14/0
                                                                                                      Open esophagectomy                          31      58.6 (33.7--76.8)                            10/21       0/3/16/11/0                 12/19/0
  Sihag et al[@b34-ott-9-6751]          2015   USA                          Prospective   6           Minimally invasive esophagectomy            814     63.3±10.7                                    658/156     NA                          NA
                                                                                                      Open esophagectomy                          2,966   63.2±10.2                                    2,492/474                               
  Smithers et al[@b35-ott-9-6751]       2007   Australia                    Prospective   6           Total minimally invasive esophagectomy      23      61 (38--77)                                  20/3        1/3/5/10/0                  16/3/4
                                                                                                      Thoracoscopic-assisted esophagectomy        309     64 (27--85)                                  248/61      21/66/96/100/8              199/74/18
                                                                                                      Open esophagectomy                          114     62.5 (29--81)                                104/10      2/6/28/73/2                 100/7/4

**Abbreviations:** m/f, male/female; NOS, Newcastle-Ottawa quality assessment Scale; RCT, randomized controlled trial; IQ, interquartile; SD, standard deviation; TNM, tumor node metastasis; NA, not available.

###### 

All outcomes of interest

  Outcome                         Number of studies   Cases   MD/RR/OR/HR   95% CI             Heterogeneity             Test for overall effect   Favors group
  ------------------------------- ------------------- ------- ------------- ------------------ ------------------------- ------------------------- --------------
  Operative blood loss            4                   491     MD =−283.61   −451.69, −115.52   *P*\<0.0001, *I*^2^=87%   *Z*=3.31, *P*=0.0009      MIE
  Operation time                  5                   561     MD =44.42     10.95, 77.88       *P*=0.002, *I*^2^=77%     *Z*=2.60, *P*=0.009       OE
  Number of lymph node harvest    4                   491     MD =−0.80     −4.63, 3.03        *P*=0.01, *I*^2^=73%      *Z*=0.41, *P*=0.68        None
  R0 resection                    7                   813     RR =1.03      0.98, 1.08         *P*=0.57, *I*^2^=0%       *Z*=1.25, *P*=0.21        None
  Reoperation                     8                   4,530   OR =1.10      0.59, 2.04         *P*=0.02, *I*^2^=57%      *Z*=0.29, *P*=0.77        None
  In-hospital mortality           15                  5,541   OR =0.84      0.60, 1.19         *P*=0.96, *I*^2^=0%       *Z*=0.97, *P*=0.33        None
  Respiratory complication        19                  5,910   RR =0.74      0.58, 0.94         *P*\<0.0001, *I*^2^=67%   *Z*=2.45, *P*=0.01        MIE
  Cardiovascular complication     13                  5,217   OR =0.90      0.64, 1.28         *P*=0.32, *I*^2^=12%      *Z*=0.56, *P*=0.57        None
  Anastomotic leakage             17                  5,754   OR =0.84      0.59, 1.18         *P*=0.14, *I*^2^=27%      *Z*=1.00, *P*=0.32        None
  Anastomotic stricture           7                   982     OR =1.76      0.78, 3.97         *P*=0.0006, *I*^2^=67%    *Z*=1.35, *P*=0.18        None
  Chyle leakage                   9                   1,208   OR =0.90      0.47, 1.74         *P*=0.68, *I*^2^=0%       *Z*=0.30, *P*=0.76        None
  Recurrent laryngeal paralysis   6                   672     OR =1.31      0.67, 2.55         *P*=0.38, *I*^2^=6%       *Z*=0.80, *P*=0.43        None
  Overall survival                3                   591     HR =0.54      0.42, 0.70         *P*=0.76, *I*^2^=0%       *Z*=4.58, *P*\<0.00001    MIE

**Abbreviations:** CI, confidence interval; RR, relative ratio; OR, odds ratio; HR, hazard ratio; MD, mean difference; MIE, minimally invasive esophagectomy; OE, open esophagectomy.
